TY - JOUR
T1 - An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
T2 - A Systematic Review of Clinical Trials
AU - Alfayez, Abdulrahman I.
AU - Alfallaj, Jawaher M.
AU - Mobark, Mugahid A.
AU - Alalwan, Abdullah A.
AU - Alfayez, Osamah M.
N1 - Publisher Copyright:
© 2024 Bentham Science Publishers.
PY - 2024
Y1 - 2024
N2 - Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of liver disease, specifically chronic liver disease. Type 2 diabetes (T2DM) is associated with the risk of NAFLD given that patients usually have insulin resistance as one of the observed complications with NAFLD. Hypoglycemic agents, including sodium glucose cotransporter 2 (SGLT-2), have shown to improve NAFLD. The objective of this study is to evaluate the effect of SGLT-2 inhibitors on NAFLD patients’ outcomes, whether they have T2DM or not. We conducted a comprehensivesearch using the PubMed and Ovid databases to identify published studies that addressed the use ofSGLT-2 inhibitors in NAFLD patients. The outcomes assessed include changes in liver enzymes, lipid profiles, weight changes, the fibrosis-4-index (FIB4), and magnetic resonance imaging protondensity-based fat fraction (MRI-PDFF). Only clinical trials that met the quality measures were included in this review. Out of 382 potential studies, we included 16 clinical trials that discussed the use of SGLT-2 inhibitors in NAFLD patients. A total of 753 patients were enrolled in these trials. The majority of the trials reported positive effects of SGLT-2 inhibitors on liver enzymes; alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase. All 10trials that reported changes in body mass index (BMI) from baseline showed a statistically significantr eduction with SGLT-2 inhibitor use, while 11 studies reported a significant increase in high density lipoprotein (HDL) levels, 3 studies reported a reduction in triglycerides (TG) levels, and 2studies showed a decrease in low density lipoprotein (LDL) levels. The available evidence shows that the use of SGLT-2 inhibitors in NAFLD is associated with positive outcomes on liver enzymes, lipid profiles, and BMI. Further studies with larger sample size and longer follow-up time are warranted.
AB - Non-alcoholic fatty liver disease (NAFLD) is one of the main causes of liver disease, specifically chronic liver disease. Type 2 diabetes (T2DM) is associated with the risk of NAFLD given that patients usually have insulin resistance as one of the observed complications with NAFLD. Hypoglycemic agents, including sodium glucose cotransporter 2 (SGLT-2), have shown to improve NAFLD. The objective of this study is to evaluate the effect of SGLT-2 inhibitors on NAFLD patients’ outcomes, whether they have T2DM or not. We conducted a comprehensivesearch using the PubMed and Ovid databases to identify published studies that addressed the use ofSGLT-2 inhibitors in NAFLD patients. The outcomes assessed include changes in liver enzymes, lipid profiles, weight changes, the fibrosis-4-index (FIB4), and magnetic resonance imaging protondensity-based fat fraction (MRI-PDFF). Only clinical trials that met the quality measures were included in this review. Out of 382 potential studies, we included 16 clinical trials that discussed the use of SGLT-2 inhibitors in NAFLD patients. A total of 753 patients were enrolled in these trials. The majority of the trials reported positive effects of SGLT-2 inhibitors on liver enzymes; alanine transaminase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase. All 10trials that reported changes in body mass index (BMI) from baseline showed a statistically significantr eduction with SGLT-2 inhibitor use, while 11 studies reported a significant increase in high density lipoprotein (HDL) levels, 3 studies reported a reduction in triglycerides (TG) levels, and 2studies showed a decrease in low density lipoprotein (LDL) levels. The available evidence shows that the use of SGLT-2 inhibitors in NAFLD is associated with positive outcomes on liver enzymes, lipid profiles, and BMI. Further studies with larger sample size and longer follow-up time are warranted.
KW - diabetes
KW - nonalcoholic fatty liver disease
KW - nonalcoholic steatohepatitis
KW - sodium glucose cotransporter 2 inhibitors
KW - systematic review
KW - type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85186677920&partnerID=8YFLogxK
U2 - 10.2174/1573399820666230525150437
DO - 10.2174/1573399820666230525150437
M3 - Review article
C2 - 37231725
AN - SCOPUS:85186677920
SN - 1573-3998
VL - 20
SP - 131
EP - 144
JO - Current Diabetes Reviews
JF - Current Diabetes Reviews
IS - 2
M1 - e250523217349
ER -